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(Affiliations continued on next page)SUMMARYMicroRNAs (miRNAs) are small non-coding RNAs involved in post-transcriptional gene regulation that have a
major impact on many diseases and provide an exciting avenue toward antiviral therapeutics. From patient
transcriptomic data, we determined that a circulatingmiRNA,miR-2392, is directly involvedwith severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) machinery during host infection. Specifically, we show
thatmiR-2392 is key in driving downstream suppression ofmitochondrial gene expression, increasing inflam-
mation, glycolysis, and hypoxia, as well as promoting many symptoms associated with coronavirus disease
2019 (COVID-19) infection. We demonstrate that miR-2392 is present in the blood and urine of patients pos-
itive for COVID-19 but is not present in patients negative for COVID-19. These findings indicate the potential
for developing aminimally invasive COVID-19 detectionmethod. Lastly, using in vitro human and in vivo ham-
ster models, we design a miRNA-based antiviral therapeutic that targets miR-2392, significantly reduces
SARS-CoV-2 viability in hamsters, and may potentially inhibit a COVID-19 disease state in humans.INTRODUCTION
In fall 2019, a zoonotic spillover event led to the first known hu-
man infection with the severe acute respiratory syndrome coro-
navirus 2 (SARS-CoV-2), and subsequent human-to-human
transmission triggered a pandemic that led to a worldwide healthC
This is an open access article under the CC BY-Ncrisis from the resulting disease, called coronavirus disease
2019 (COVID-19) (Huang et al., 2020; Zhu et al., 2020). COVID-
19 causes substantial pulmonary disease but can also cause
systemic health risks from extrapulmonary manifestations. Its ef-
fects entangle the entire body, including the cardiovascular,
gastrointestinal, and hematological systems, and may lead toell Reports 37, 109839, October 19, 2021 ª 2021 The Author(s). 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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OPEN ACCESSlong-lasting effects after the virus has left the body, known as
PASC (post-acute sequela of COVID-19) (Carfı̀ et al., 2020; Ja-
cobs et al., 2020). SARS-CoV-2 is classified as a member of
the Coronaviridae family, viruses with a enveloped positive-
stranded RNA with the ability to infect cross-species (V’kovski
et al., 2021). Although the current vaccines represent a favorable
milestone, additional data are required to demonstrate their
long-term effectiveness against SARS-CoV-2 and protection
against new strains. To prevent an endemic, the global eradica-
tion of COVID-19 will require a wide majority of the world’s
population to be vaccinated to achieve herd immunity. Unfortu-
nately, a portion of the population will not get vaccinated. There-
fore, strategies for therapeutic options against COVID-19 are
particularly relevant and important to explore to treat severe ill-
nesses and overcome this global pandemic. Currently, most an-
tivirals are repurposed drugs used for other diseases and have
shown limited clinical efficacy, such as remdesivir (Abdelrahman
et al., 2021). This brings a needed urgency to develop antivirals
specifically designed against SARS-CoV-2.
A potential avenue for an alternative antiviral agent is to target
specific microRNAs (miRNAs) associated with SARS-CoV-2
infection and subsequent manifestation of COVID-19. miRNAs
are non-coding RNAs involved with the regulation of post-tran-
scriptional gene expression, and they can affect entire pathways
related to viruses and diseases (Jiang et al., 2009; Trobaugh and
Klimstra, 2017). Each miRNA can target multiple messenger
RNAs (mRNAs), and altogether, miRNAs are predicted to regu-
late more than half of the human transcriptome (Friedman
et al., 2009). Recent evidence has shown that different diseases,
including COVID-19, lead to distinct complements of miRNAs in
the blood (Nersisyan et al., 2020; Saçar Demirci and Adan, 2020;
Teodori et al., 2020). These circulating miRNAs are highly stable
and have the potential to be used for minimally invasive detec-
tion, as biomarkers, and as therapeutic targets (Tribolet et al.,
2020). The interactions between miRNAs and viruses have re-
vealed a multifaceted relationship. Specifically, viruses have
been shown to avoid the immune response by leveraging cellular
miRNAs to complete their replication cycle (Trobaugh and Klim-
stra, 2017). The following mechanisms are central to the interac-
tion of viruses and miRNAs: (1) miRNA processing can be2 Cell Reports 37, 109839, October 19, 2021blocked by viruses interacting with key proteins, such as Dicer
and associated proteins; (2) viruses can sequester miRNAs, re-
sulting in dysregulation of specific target mRNAs; (3) viruses
can use miRNAs to redirect regulatory pathways of other miRNA
targets to provide survival advantages; and (4) viruses can
directly encode miRNA precursors that are processed by the ca-
nonical miRNA cellular pathway and have well-defined functions
to specifically target and regulate the viral replicative cycle
(Schult et al., 2018; Trobaugh and Klimstra, 2017).
Here, we report on amiRNA,miR-2392, thatmay directly regu-
late and drive a COVID-19 response. This miRNA is predicted
from COVID-19 RNA sequencing (RNA-seq) patient data that re-
sulted in multiple miRNAs being suppressed/inhibited (miR-10,
miR-10a-5p, miR-1-3p, miR-34a-5, miR-30c-5p, miR-29b-3p,
miR-155-5p, and miR-124-3p) and one miRNA being upregu-
lated (miR-2392). With further examination, we hypothesize
miR-2392 to be a key miRNA involved with COVID-19 progres-
sion. Specifically, miR-2392 drives downstream suppression of
mitochondria activity while increasing inflammation, glycolysis,
and hypoxia. miR-2392 upregulation is concomitant with symp-
toms associated with COVID-19 in the host. Patient blood and
urine data show that miR-2392 circulates in COVID-19 patients
and its concentration increases as a function of viral load. Our re-
sults demonstrate that miR-2392 may be used as an effective
biomarker of COVID-19. Furthermore, we have started develop-
ment of a miR-2392 inhibitor and provide evidence that it re-
duces SARS-CoV-2 viability in targeted viral screens in vitro
and reduces the impact of infection in animal models. With
further development, this miR-2392 inhibitor may represent an
effective antiviral therapeutic and limit a negative host response
from COVID-19.
RESULTS
Identification of key miRNAs associated with COVID-19
infection
Currently, most publications associated with miRNAs and
SARS-CoV-2 are based on in silico predictions. To identify miR-
NAs that may be involved in driving COVID-19 severity in the
host, we examined publicly available bronchial alveolar lavage
Figure 1. Key miRNA signature as predicted from bronchial alveolar lavage fluid (BALF) RNA-seq data in patients with COVID-19
(A) Predicted upstream regulators determined by IPA consistent with the transcriptional response from differentially expressed genes (FDR < 0.05; outer ring) in
patients (n = 13). Eight miRNAs were among the key regulators in response to COVID-19 (inner ring).
(B) Major biological responses from dysregulation of this eight-miRNA signature drive immune- and inflammatory-related pathways, as well as mitochondrial
dysfunction determined by IPA.
(C) Pathway regulation by miR-2392 from BALF RNA-seq data determined by IPA.
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OPEN ACCESSfluid (BALF) RNA-seq data. Differential gene expression was as-
sessed using a 1.2-fold change for p values less than 0.01,
revealing 42 increased and 347 decreased genes compared
with controls. Using the upstream regulator analysis from the
Ingenuity Pathway Analysis (IPA) knowledge database, miRNAs
from differentially expressed genes (false discovery rate [FDR] <
0.05) from patients positive for COVID-19 were inferred. Eight
miRNAs were predicted to drive significant changes in patients
positive for COVID-19 with the downregulation of seven miRNAs
(miR-10, miR-1, miR-34a-5p, miR-30c-5p, miR-29b-3p, miR-
124-3p, and miR-155-5p) and upregulation of a single miRNA,
miR-2392 (Figure 1A). Using IPA’s downstream effects analysis
to predict biological processes from the combined suppression
of the seven miRNAs and upregulation of miR-2392 resulted in
increased inflammation, immune suppression, and suppression
of mitochondrial activity (Figures 1B and 1C).
In support of these findings, previous studies have shown up-
regulation ofmiR-10, miR-124, or miR-1 has antiviral roles during
infection (Hu et al., 2020; Sardar et al., 2020; Yang et al., 2016)
and upregulation of miR-30 and miR-155 causes suppression
of other coronaviruses (Dickey et al., 2016; Ma et al., 2018).
The one miRNA predicted to be upregulated in COVID-19 pa-
tients from the BALF data was miR-2392. Although limited, theexisting literature onmiR-2392 demonstrates it is related tomito-
chondrial suppression and increased glycolysis (Fan et al.,
2019), as well as circulating factors related to negative health
risks (Chen et al., 2013; Fan et al., 2019; Li et al., 2017; Yang
et al., 2019).
We performed pathway analysis with miR-2392 targets to
determine its potential impact on the host. Upregulation of
miR-2392 in the BALF RNA-seq dataset affected many down-
stream targets and pathways related to negative health out-
comes (Figure 1C). This includes mitochondrial suppression
and activation of factors related to reactive oxygen species
(ROS). Because it is known that miR-2392 directly interacts
with mitochondrial DNA (mtDNA) to inhibit the levels of oxidative
phosphorylation (OXPHOS) transcripts (Fan et al., 2019), this
could be a compensatory response to the inhibition of mitochon-
drial bioenergetics.
Glycolytic pathways (Figure 1C) are also upregulated in asso-
ciation with increased miR-2392. miR-2392 drives hexokinase 2
(HK2) and pyruvate kinase (PKM), both of which positively regu-
late glycolysis. HK2 produces a primary regulator of glycolysis,
glucose-6-phosphate, and enhances guanosine diphosphate
(GDP)-glucose biosynthesis. GDP-glucose is a nucleotide sugar
and an essential substrate for all glycosylation reactions (i.e.,Cell Reports 37, 109839, October 19, 2021 3
Figure 2. Cross-species and viral integration of miR-2392
(A) Conservation of miR-2392 across species determined by the UCSC Genome Browser. Boxes (-) represent aligning and conserved sequence regions. The
double horizontal line (=) shows both the genome and the query have an unalignable sequence between regions of the aligned sequence, a double-sided
insertion. Single lines (-) indicate gaps.
(B) Expression of MEG3, the miR-2392 host gene, in different tissues from healthy patients.
(C) Potential binding sites of miR-2392 visualized across the SARS-CoV-2 genomes (NC045512.2 from GISAID). Average miRanda scores are for hits within the
100 bp window. The top three hits are shown.
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OPEN ACCESSglycosylation of viral spike proteins). PKM is essential for the pro-
duction of ATP in glycolysis that catalyzes the transfer of the
phosphate group from phosphoenolpyruvate to ADP to make
ATP. Themechanism of howmiR-2392 is driving these pathways
is not clearly understood, but one possibility could be stabiliza-
tion of glycolytic transcripts.
Overall, the observed upregulation of glycolysis and antiviral
effects related to miR-2392 suppression are consistent with
the recently documented role of glucose metabolism in the pro-
gression of viral infection and poor outcome of COVID-19
(Ardestani and Azizi, 2021). It is also consistent with the reported
effects of glycolysis suppression by the glucose analog 2-deoxy-
D-glucose (2-DG) that was shown to suppress SARS-CoV-2
replication in vitro (Ardestani and Azizi, 2021). These and miR-
2392 data indicate targeting of glucose metabolismmight signif-
icantly affect SARS-CoV-2 infections.
Targets implicated in antioxidant N-acetyl cysteine (NAC) ther-
apy are to be upregulated (Figure 1C). These include adhesion
molecules of activated endothelial cells such as intercellular
adhesion molecule 1 (ICAM1), vascular cell adhesion molecule
1 (VCAM1), and E-selectin, which allow attachment of hematopoi-
etic immune and non-immune cells to the endothelial surface and
thus contribute to inflammation and activation of the coagulation
cascade. Powerful antioxidants such as NAC potentially coun-
teract COVID-19 infections by suppressing viral replication via
improving the intracellular thiol redox ratio as a precursor for the
major thiol antioxidant glutathione (Ho and Douglas, 1992) and in-
hibiting the nuclear factor kB (NF-kB) pathway (Poppe et al.,4 Cell Reports 37, 109839, October 19, 20212017). Inhibition of the NF-kB pathway reduces inflammatory
damage by altering the glutathione and glutathione disulfide ratio
(Aykin-Burns et al., 2005; Jia et al., 2010). These results were in
line with the role of miR-2392 in reducing the activities of electron
transport chain complexes and enhancing glycolysis. Inflamma-
tory pathways and others that are observed with COVID-19 infec-
tion were also seen to be activated downstream of miR-2392.
Conservation of miR-2392 between species and its
predicted interactions with the SARS-CoV-2 genome
Viral miRNAs can facilitate interspecies viral transmission
because of the high conservation of miRNAs among species
and the ability of viruses to integrate miRNAs into their own
genome (Saçar Demirci and Adan, 2020; Schult et al., 2018).
This has been shown to assist viral replication and evasion of
the immune system (Islam and Islam, 2021). Thus, we analyzed
the conservation of human miR-2392 across species and the
integration of miR-2392 into the SARS-CoV-2 genome (Figure 2).
We determined the conservation of miR-2392 across different
species using the UCSC (University of California Santa Cruz)
Genome Browser (Kent et al., 2002). The mature 20 base-pair
miR-2392 is derived from an 84 base-pair region of the 30 UTR in
a long non-coding RNA gene, maternally expressed 3 (MEG3),
and is located in an imprinted region, DLK1-DIO3, that contains
three clusters with 51 other miRNAs (Figures 2A and 2B). A base-
wise evolutionary comparison showed miR-2392 is highly
conserved among non-human primates such as dogs, cats, and
ferrets, species known to be infected with SARS-CoV-2, whereas
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OPEN ACCESSmice and rats, species not affected byCOVID-19 (Johansen et al.,
2020), have poor conservation with miR-2392.
The impact of miR-2392’s host gene, MEG3, within normal tis-
sues was determined by GTEx data (GTEx Consortium, 2020).
For most healthy tissues, MEG3 either was not detected or
was expressed at low levels (Figure 2B). This can imply that
miR-2392 does not seem to significantly affect normal tissues.
We used miRanda (Enright et al., 2003) to identify potential
miR-2392 binding sites with respect to the SARS-CoV-2 refer-
ence genome (Wuhan-Hu-1; NC045512.2) and lineages of
concern. The miR-2392 seeding region is heavily integrated
and conserved in different viral strains (Figure 2C). The three
best scores are located in the NSP2, NSP3, and E genes.
Notably, these regions were conserved among 6 concerning lin-
eages represented by 14 recent genomes available from the
Global Initiative on Sharing All Influenza Data (GISAID) (Shu
and McCauley, 2017).
miR-2392 targets mitochondrial and inflammatory
pathways associated with SARS-CoV-2
To determine a more comprehensive impact of miR-2392-
affected pathways in COVID-19 patients, gene targets were pre-
dicted by seed-region base-pairing in the miRmap database
(Vejnar and Zdobnov, 2012). This list was refined by overlap in
several miRNA databases, including miRmap, miRwalk (Dweep
and Gretz, 2015), miRDB (Chen andWang, 2020), miRnet (Chang
et al., 2020), andClueGo (Bindea et al., 2009).WeaddedRNA-seq
analysis of 39 autopsy tissue samples from the heart, lung, kidney,
liver, and lymph node of COVID-19-positive patients with high or
low viral loads (Park et al., 2021). miR-2392 gene targets (375
genes) were visualized using volcano plots (Figures 3A–3F).
To ascertain the systemic impact on miR-2392 gene targets in
COVID-19, we performed pathway analysis of nasopharyngeal
swab samples taken from living donors with and without
COVID-19, using viral load as the independent variable (high,
medium, low, or other virus). The differentially expressed genes
(FDR < 0.05) in at least one comparison of COVID-19-positive
patients or other detected viruses were found to separate into
six distinct hierarchical clusters annotated using ShinyGO (Ge
et al., 2020) (Figure 3G). Most upregulated miR-2392 targets
participate in immune and inflammatory pathways. Downregu-
lated targets are involved in mitochondrial function, oxidative
stress, the cell cycle, developmental biology, and ubiquitin bind-
ing, all pathways recently associated with SARS-CoV-2 infection
(Hemmat et al., 2021). These data demonstrate that miR-2392
may target several pathways related to perpetuating SARS-
CoV-2 infection. For all tissues excluding the lymph nodes,
higher viral loads are associated with greater differential expres-
sion of miR-2392-regulated gene targets.
Because miR-2392 was shown to directly target the transcrip-
tionofmtDNAgenes (Fanet al., 2019),weevaluatedmitochondrial
miR-2392 targets in our datasets using MitoCarta (Rath et al.,
2021) (Figure 3H). This revealed 14 genes harboring miR-2392
seed sequences that were significantly dysregulated in the nasal
and heart samples. In nasal samples, SLC25A28, a mitoferrin
that mediates mitochondrial iron transport, was strongly upregu-
lated, along with IBA57, which is involved in iron sulfur assembly.
The mitochondrial outer membrane protein import complex sub-unit TOMM20, cytochrome c oxidase (complex IV) subunit
COX6B1, and mitochondrial transcription factor COT-2 (NR2F2)
were strongly downregulated. In the heart, the folate enzyme
MTHFD2L (methylenetetrahydrofolate dehydrogenase) was upre-
gulated, whereas all other nuclear-coded mitochondrial genes
were downregulated. Downregulated heart mitochondrial genes
includedNDUFS5 (complex I subunit), COX6B1andCOX10 (com-
plex IVstructural andassembly subunits),CKMT1A (mitochondrial
creatine kinase),MRPL34 (mitochondrial ribosome small subunit),
COT-2 (NR2F2), AK4 and MSRB3 (adenylate kinase 4 and methi-
onine-R-sulfoxide reductase, respectively, which mitigate oxida-
tive stress), MRS2 (magnesium transporter), and CLIC4 (chloride
channel). The kidney showed mild upregulation of complex I and
single methyl group metabolism but downregulation of complex
IV (COX10), regulatory factor (COT-2), and iron sulfur center pro-
tein (IBA57). Hence, SARS-CoV-2 seems to downregulate nuclear
mitochondrial gene transcription in the more oxidative organs,
heart and kidney, as well as in nasal tissues.
Because inflammation is a key component of COVID-19, we
overlaid known inflammatory genes determined from Loza
et al. (2007) with miR-2392 targets (Figure 3I). From analysis at
the mRNA level, most complement pathway genes are upregu-
lated in the tissue samples analyzed. These changes could be
compensatory, because proteins encoded by the genes could
be downregulated as a function of traditional miRNA effects.
The responses reflect the importance of degrees of inflammation
for mediation of disease severity in COVID-19 patients and a key
modulatory role of miR-2392 in this context.
Proteomic and transcriptomic analysis in blood from COVID-
19 patients using COVIDome (Sullivan et al., 2021) revealed
interesting patterns between RNA and protein levels for miR-
2392 targets from miRmap, ClueGO, miRwalk, miRnet, and
miRDB (Figures 3J and 3K). Several miR-2392 targets in tissue
show a significant transcriptional increase in COVID-19-positive
samples, with small to no changes on the proteomics level:
PLK1, CD38, PYCR1, RNASE1, BIRC5, RRM2, and SIGLEC1
(Figure 3J). Interestingly, all these genes were also positively
regulated for most tissues when considering only miR-2392
gene targets with miRmap (Figures S1 and S2). The miR-2392
targets CXCL10, STAT1, IFIT3, and C1QC were positively regu-
lated at both the protein and the gene levels for the blood and
other tissues. The correlation between RNA and protein expres-
sion was close for miR-2392 targets and was slightly stronger in
COVID-19-negative samples (correlation score [cor] = 0.209,
p = 4e10) versus COVID-19-positive samples (cor = 0.205,
p = 8e10) (Figure 3K). Further investigation is needed to un-
derstand whether increased levels of miR-2392 could poten-
tially bind genes’ mRNAs at a higher rate, and therefore prevent
translation to protein, or whether other mechanisms prevent
mRNA translation to protein.
Overexpression of miR-2392 simulates a phenotype
similar to COVID-19 infection
To determine whether miR-2392 upregulation would elicit ef-
fects similar to a COVID-19 infection, cells were treated with a
miR-2392 mimic. Using RNA-seq, 649 genes had a fold change
greater than ±1.2 and a p value less than 0.05 (Figure 4A), and
many genes were miR-2392-predicted targets (Figure 4B).Cell Reports 37, 109839, October 19, 2021 5
Figure 3. Gene targets of miR-2392 in COVID-19 patients, as well as mitochondrial and inflammatory genes
(A–F) Volcano plots for differential gene expression from (A) nasopharyngeal swab and autopsy COVID-19 patient tissues from the (B) heart, (C) kidney, (D) liver,
(E) lung, and (F) lymph node separated by viral load.
(G) Heatmaps displaying t score statistics when comparing viral load versus negative patient samples for nasopharyngeal swab and autopsy tissues. Main gene
clusters were determined by k-means clustering and annotated using ShinyGO (Ge et al., 2020) above the heatmap.
(H and I) miR-2392 gene targets for (H) mitochondrial or (I) inflammatory genes are displayed. Genes shown have at least one comparison with a FDR < 0.05 when
comparing COVID-19 patients (high, medium, or low viral loads) to non-infected patients (none). MiRmap-only heatmaps for miR-2392 mitochondrial and in-
flammatory gene targets are available in Figures S1 and S2, respectively.
(J) Scatterplot of log2-fold changes in RNA and protein for miR-2392 targets for genes differentially expressed at the RNA level. Student’s t test, RNA p% 0.05, no
limitation on the protein p value.
(K) Scatterplot of log2-transformed medians in RNA and protein. COVID-19-positive samples (orange) or COVID-19-negative samples (gray).
Student’s t test is used in fold change calculations. Shape size and opacity represent RNA fold change values (circle, positive; triangle, negative). Pearson
correlations are displayed in the top corner.
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OPEN ACCESSThese genes were then compared with whole-cell proteome
data from a human-derived cell culture model of a SARS-CoV-
2 infection profile (Stukalov et al., 2021), which found 10
overlapping gene/proteins that were significantly altered:
KIF22, FKBP14, RAD51, AFAP1, ZCCHC17, ZWINT, MAGED1,
CENPF, TMEM70, and NFKB2 (Figure 4C). Because viral infec-
tion may alter post-translational modification, including ubiqui-
tination, we analyzed the ubiquitinome of a SARS-CoV-2
human-derived cell culture model and observed several altered
proteins in normalized ubiquitin abundance that were also dys-
regulated genes by miR-2392 overexpression. We also found
miR-2392 overexpression affected genes involved with mito-
chondria and inflammation (Figures 4D–4F).6 Cell Reports 37, 109839, October 19, 2021To determine whether there was a direct correlation between
miR-2392 overexpression and SARS-CoV-2 infection, we
compared gene expression changes or overlap in statically sig-
nificant canonical gene sets with our fast preranked gene set
enrichment analysis (fGSEA) analysis. Published data from
Blanco-Melo et al. (2020) showed a statistically significant and
positive correlation of the miR-2392 treatment to A549 and
Calu-3 cells infected with SARS-CoV-2 (Figures 4G and 4H), as
well as in lung biopsies post-mortem from two patients positive
for COVID-19 (Figure 4H). Using nasal swab samples, there
was a significant and positive correlation between patients
withmedium and low viral loads comparedwith non-infected pa-
tients (Figures 4I and 4J). Additional miR-2392 correlation to
Figure 4. Increased miR-2392 expression in vitro mimics a COVID-19 phenotype
(A–F) RNA-seq volcano plots in cells overexpressing miR-2392.
(G–J) Correlation plot between miR-2392 overexpression and related SARS-CoV-2 datasets. Circle size is proportional to the correlation coefficient. Statistical
significance was determined using a two-tailed Student’s t test; *p < 0.05, **p < 0.01, and ***p < 0.001.
(K–O) Dot plots for statistically significant gene sets determined by fast preranked gene set enrichment analysis (fGSEA). NES, nominal enrichment score.
(P and Q) Predicted miR-2392 targets by the MIRDIP algorithm that are downregulated in the overexpression experiments. The putative miR-2392 mRNA targets
belonging to the consensus transcriptomic networks observed in SARS-CoV-2, Middle East respiratory syndrome (MERS), and influenza infections of different
human cells are represented in a Venn diagram in the upper part of (P).
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OPEN ACCESSSARS-CoV-2 infections used RNA-seq data from multiple tis-
sues (heart, kidney, liver, lymph node, and lung) obtained during
autopsies of COVID-19 patients with high or low viral loads (Fig-
ures 4I and 4J). There was a positive correlation to lung and
lymph node tissues with miR-2392 expression. Interestingly,
there was a significant and positive correlation to liver tissue
when comparing gene fold change values (Figure 4I), but not
when comparing C2 curated biological gene sets (Figure 4J). In
contrast, a negative correlation to heart tissue was observed.
Statistically significant pathways that were enriched due to
miR-2392 treatment were examined using fGSEA (Figures 4K–
4O). miR-2392 treatment induced a pathway response that
was significantly related to SARS-CoV-2 pathways. One obvious
relationship shows that Reactome SARS-CoV-2 pathways were
significantly activated for the miR-2392-treated cells compared
with the controls (Figures 4K and 4L). Significant Hallmark path-
ways (Figure 4N) show upregulation of hypoxia (Herrmann et al.,
2020), glycolysis (Ardestani and Azizi, 2021), and cell-cycle path-
ways (Su et al., 2020) that have been reported to be associated
with COVID-19. Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathway analysis (Figure 4M) indicates miR-2392 over-expression highly upregulated systemic lupus erythematosus,
which has been reported to occur in COVID-19 patients, who
have shown similar pathologies because of the increase of
inflammation (Zamani et al., 2021).
Lastly, we determined downregulated targets in the cell lines
after miR-2392 overexpression. A regulatory network was built
by including the predicted miR-2392 targets in the microRNA
Data Integration Portal (MIRDIP) that were also downregulated
in the overexpression cell model, as well as from the recently
described consensus transcriptional regulatory networks in co-
ronavirus-infected cells (Ochsner et al., 2020) (Figure 4P). The
gene enrichment analysis of these putative miR-2392 targets
showed the presence of Gene Ontology (GO) terms related to
RNA metabolism, transcription, ribosome activity, and the Golgi
complex (Figure 4Q).
Circulating miR-2392 and the suppression of other
miRNAs in COVID-19-infected patients
To demonstrate the presence of circulating miR-2392 in
COVID-19-infected patients, we quantified miR-2392 by droplet
digital PCR (ddPCR) in serum, urine, and nasopharyngeal swabCell Reports 37, 109839, October 19, 2021 7
Figure 5. Circulating miR-2392 comparing
patients positive and negative for COVID-19
Droplet digital PCR (ddPCR) for miR-2392 on
serum, urine, and nasopharyngeal swab samples
(including seasonal coronavirus) from COVID-19-
positive or COVID-19-negative patients.
(A) miR-2392 levels from COVID-19-positive
(SARS-CoV-2) or COVID-19-negative (neg) pa-
tients. Unadjusted t tests for each tissue or
adjusted statistics with a mixed model corrected
for age and sex are shown.
(B) ROC curve for miR-2392 in each tissue.
(C) Tissue comparisons for multiple categories. N,
COVID-19 negative; p, COVID-19 positive; Pint,
intubated patients; outp, outpatient; ICU, intensive
care unit/inpatient; Cold, common cold coronavi-
ruses; NL63, NL63 coronavirus; CoV-2, SARS-
CoV-2. For all plots, *p < 0.05, **p < 0.01, and ***p <
0.001. Sample numbers: all serum patient groups
(n = 10), CoV-2 (n = 10), Cold (n = 6), NL63 (n = 6),
inpatient COVID-19-positive (n = 10) or COVID-19-
negative (n = 10) urine samples, and outpatient
COVID-19-positive (n = 15) or COVID-19-negative
(n = 11) urine samples.
(D) miR-2392 in monocytes from healthy donors (n
= 3 biological replicates and n = 3 technical repli-
cates for each donor) infected with the SARS-CoV-
2 reference strain and P1 variant. Comparisons
with three other miRNAs were made: miR-1-3p




OPEN ACCESSpatient samples (Figure 5). Serum was obtained from patients
positive for COVID-19 with or without intubation or patients
negative for COVID-19. Urine samples were from inpatients or
outpatients positive for COVID-19, inpatients negative for
COVID-19, or COVID-19-negative healthy donors. Nasal swabs
were from patients positive for COVID-19, common cold coro-
navirus (229E, HKU1, and OC43), or respiratory illness/corona-
virus (NL63).
We observed a statistically significant increase of miR-2392 in
patients positive for COVID-19 fromboth the serum and the urine
samples (Figure 5A). In addition, receiver operating character-
istic (ROC) curve analysis revealed that miR-2392 is significantly
associated with SARS-CoV-2 infection in patients (Figure 5B) in
all tissues. miR-2392 levels were higher for conditions associ-
ated with infection of more severely affected patients (i.e., intu-
bated or intensive care unit [ICU]) (Figure 5C). Low levels of
miR-2392 appeared in the nasopharyngeal location, with no sig-
nificant differences occurring between seasonal coronavirus
samples. To study more specific tissue origins for miR-2392,
we infected monocytes obtained from healthy donors with the
SARS-CoV-2 reference strain (i.e., the strain from Wuhan) and
P1 variant (Figure 5D). We saw an increase of miR-2392 with
the reference SARS-CoV-2-infected cells and a significant in-
crease in the P1 variant-infected cells. Previously, it was shown
that thesemonocytes infectedwith SARS-CoV-2 have increased
pro-inflammatory cytokine and glycolysis expression, with the
effects inhibited by glycolysis inhibitors (Codo et al., 2020).
Because we hypothesize that miR-2392 is a primary initiator
for systemic impact of the infection, this might indicate that8 Cell Reports 37, 109839, October 19, 2021miR-2392 does not strongly appear until the virus has estab-
lished its presence in the body.
We also quantified miR-1-3p (Figure S3), miR-155-5p (Fig-
ure S4), and miR-124-3p (Figure S5), which were predicted to
be inhibited by COVID-19 infection (Figure 1A). miR-1-3p and
miR-155-5p were significantly suppressed in the serum, with
no differences in the urine or nasopharyngeal samples (Figures
S3 and S4A–S4C). miR-1-3p is known to be beneficial for cardio-
vascular functions, with its inhibition leading to heart failure and
disease (Condorelli et al., 2010). When quantifying miR-1-3p in
the SARS-CoV-2-infected monocytes, we observe a significant
decrease with the reference strain yet no difference with the
P1 variant (Figure S3D). For miR-124-3p, we observed very low
amounts (on average, <2 copies/5 ng of RNA) for all conditions,
which indicates that miR-124-3p is not circulating for any
patients for any conditions observed (Figure S4D). miR-124-3p
provides an ideal miRNA-negative control candidate for SARS-
CoV-2.
Inhibiting miR-2392: An antiviral COVID-19 therapeutic
The link between miR-2392 and COVID-19 infection prompted
the development of an effective antiviral approach for COVID-
19 by inhibiting miR-2392. We used the Nanoligomer platform
to develop an effective antisense-based therapeutic against hu-
man miR-2392 (Eller et al., 2021), termed SBCov207 (Figure 6A).
The anti-miR-2392 nanoligomer was evaluated for efficacy and
toxicity against a SARS-CoV-2 infection of the human lung cell
line A549 (Figures 6B–6D). Treatment of uninfected A549 cells
showed no cytotoxicity up to 20 mM. The control nonsense
Figure 6. Anti-miR-2392 therapeutic mitigation of SARS-CoV-2 infection with in vitro and in vivo models
(A) Platform schematic for the miR-2392 inhibitor.
(B–G) Anti-miR-2392 nanoligomer inhibitor or (E–G) nonsense control applied to A549 cells infected with SARS-CoV-2 and tested for viral viability and cytotoxicity
as biological replicates (n = 3). Error bars represent the standard error for technical replicates (n = 3).
(legend continued on next page)






OPEN ACCESSnanoligomer (SBCoV208) showed no toxicity even up to 40 mM.
Treatment of A549 cells infected with SARS-CoV-2 showed
drastic improvement in cell viability, with an average of 85%
viral inhibition at 10 mM (half maximal inhibitory concentration
(IC50) = 1.15 ± 0.33 mM). In contrast, the control nanoligomer
showed significantly lower viral suppression (Figures 6E–6G).
This human cell line model reaffirms that the anti-miR-2392
(SBCov207) is effective in inhibiting SARS-CoV-2 yet does not
exhibit toxicity at the concentrations tested.
The anti-miR-2392 nanoligomer was then evaluated in a Syrian
hamster infection model (Figures 6H–6J). Six hamsters were
treated with nanoligomers for 72 h without infection, and there
was no observed change in animal behavior, indicating a lack
of obvious toxicity. Next, 30 male hamsters were divided into 5
treatment groups. The infected hamsters were given 105 pla-
que-forming units (PFUs) of the WA01/2020 strain of SARS-
CoV-2. The anti-miR-2392 nanoligomer treatment was given by
intraperitoneal (IP) injection or intranasal (IN) instillation once at
24 h before or twice at 24 h before and after viral inoculation.
Half of the hamsters in each group (n = 3) were euthanized and
necropsied on days 3 and 7 post-infection, respectively.
Loss of body weight over the course of the experiment was
<10% in all groups and was significantly different for the IN treat-
ment one day before viral inoculation (compared with the
control), but not in other groups (Figure 6H). Virus titers from
oropharyngeal swabs for IN treatment were significantly lower
(p = 0.018) than those from hamsters receiving nanoligomer IP
or PBS on day 1 post-challenge, but there were no differences
among groups on days 2 and 3 post-challenge (Figure 6I).
Although not statistically different from the control, the data indi-
cate a downward trend with nanoligomer treatment (Figure 6J),
and the total histopathological score for the IN treatment was
lower than that for the controls.
The impact of miR-2392 on diseases, relationship to
COVID-19 symptoms, and predicted FDA-approved
drugs to target miR-2392
To predict whether miR-2392 has a direct relationship to
COVID-19 symptoms, we determined the pathway and disease
relevance using miRnet. Among the diseases predicted to be
associated with miR-2392 were a surprising number of clinical
observations present in individuals with COVID-19 infection
(Figure 7A). These include heart or cardiovascular disease and
failure, both known to heavily contribute to morbidity and mor-
tality in patients with COVID-19 (Nishiga et al., 2020); hyperes-
thesia (Krajewski et al., 2021); and less common COVID-19
symptoms, such as lymphadenopathy and pharyngitis related
to sore throat (Edmonds et al., 2021), liver dysfunction (Portin-
casa et al., 2020), splenomegaly (Malik et al., 2020), CNS failure
(Mahajan and Mason, 2021; Rodriguez et al., 2020), and kidney
failure (Hultström et al., 2021).(H–J) Toxicity and efficacy of the anti-miR-2392 nanoligomer inhibitor in an in vivo
instillation 24 h before viral inoculation (IP or IN day1), 24 h prior and post-viral ch
post-viral challenge by IN instillation (PBS IN day 1 and +1, respectively). (H) Po
the maximum percentage of weight loss. (I) SARS-CoV-2 assayed by plaque assa
score for lung tissues at day 3.
IN, intranasal; IP, intraperitoneal. Error bars = standard error.
10 Cell Reports 37, 109839, October 19, 2021miR-2392 was also predicted to affect other diseases that
have been linked to COVID-19 infection in some patients. For
example, COVID-19 patients have experienced azoospermia,
which is linked to male infertility (Younis et al., 2020), an altered
menstrual cycle (Li et al., 2021), dental damage (Sirin and Ozce-
lik, 2021), and deafness or hearing loss (Koumpa et al., 2020).
Using the Kaplan-Meier Plotter (Gy}orffy, 2021) to associate
miR-2392 expression with pan-cancer patient survival (Fig-
ure S5), high expression of miR-2392 was generally related to
poor prognosis with most cancer types (p < 0.05). Intriguingly,
one miR-2392-predicted consequence was decreased antibody
levels in the blood; this might account for the reported loss of the
antibodies overtime (Gudbjartsson et al., 2020; Self et al., 2020).
Finally, using computational models, we predicted small
molecules, including FDA-approved drugs, that could inhibit
miR-2392. A state-of-the-art machine learning algorithm for
predicting missing drug targets (Galeano et al., 2021) was
applied to an association dataset between 213 small molecules
and 1,519 miRNAs from the SM2miR database (Liu et al., 2013)
(see statistics in Figures S6A and S6B), integrating chemical
and sequence similarity, respectively. The average area under
the ROC curve was of 0.877 when predicting missing small
molecule-miRNA associations (Figures S6C–S6F). The top 20
predicted small molecules (Figure 7B) include dexamethasone
(Ledford, 2020) and atorvastatin, which have shown protective
roles in COVID-19 patients (Rossi et al., 2020). Next, following
the ideas presented in Sirota et al. (2011), we performed an
analysis on the genomic signature of miR-2392 (i.e., significant
up- and downregulated genes) and predicted small molecules
that can reverse it. We screened the genomic signature of miR-
2392 against 30,000 small molecules contained in the connec-
tivity map (CMAP) (Lamb et al., 2006). The top 20 predicted
small molecules include the androgen receptor antagonist
enzalutamide and the insulin sensitizer pioglitazone (Carboni
et al., 2020), both of which are in clinical trials for COVID-19
(Figure 7C) (ClinicalTrials.gov: NCT04475601 and NCT
04604223), as well as evidence for the leukotriene inhibitor
ubenimex (Asai et al., 2020) and bacterial DNA inhibitor metro-
nidazole (Gharebaghi et al., 2020).
DISCUSSION
Although the potential eradication of the novel coronavirus
through worldwide vaccination is under way, new potent
strains of SARS-CoV-2 are constantly evolving, and there re-
mains a major need to develop effective interventional strate-
gies to minimize the damage caused by these infections.
Host-mediated lung inflammation is a driver of mortality in crit-
ically ill COVID-19 patients. Thus, it is logical to focus on ther-
apeutics that may have immunomodulating properties or
disrupt viral replication. Our research uncovers an eight-miRNAinfection hamster model. Treatments groups: SBCov207 by IP injection or IN
allenge (IP or IN day1 and +1, respectively), and 100 mL of PBS 24 h prior and
oled weights for each treatment group (n = 6, days 1–3, and n = 3, days 4–7) as
y on Vero E6 cells from oropharyngeal swabs (n = 6). (J) Histopathological total
Figure 7. Predicted impact of miR-2392 on human disease and top 20 drug compounds predicted to affect miR-2392 expression through a
machine learning approach
(A) Dot plot of manually curated diseases associated with miR-2392 predicted frommiR-2392 gene targets by miRnet. Values are plotted by p value, and the dot
size represents the number of downstream gene targets associated with disease. miR-2392 expression related to patient survival in a pan-cancer analysis is
highlighted in Figure S5.
(B) Matrix completion model scores to predict small molecules that affect miRNA expression. Higher scores indicate more predicted associations.
(C) Normalized CMAP scores using transcripts induced by miR-2392 overrepresented genes. Higher negative scores reflect a greater reversal of the miR-2392
transcriptomic signature. Further details on model statistics and performance are found in Figure S6.
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OPEN ACCESSsignature in patients with COVID-19 viral loads compared with
those without disease as predicted from RNA-seq data. The
expression of seven miRNAs was decreased (miR-10, miR-1,
miR-34a-5p, miR-30c-5p, miR-29b-3p, miR-124-3p, and
miR-155-5p), whereas a single miRNA, miR-2392, was signifi-
cantly increased (Figure 1). This key miRNA signature was
involved in major cellular and molecular mechanisms that drive
the viral-host response.
Several studies have measured differential expression of
miRNAs in COVID-19 patients and proposed their use as bio-
markers or therapeutics. Lung biopsies from 9 COVID-19 pa-
tients showed miR-26a, miR-29b, and miR-34a correlated to
endothelial dysfunction and inflammatory biomarkers (Centa
et al., 2020). Sequencing in the blood from patients with
moderate or severe COVID-19 identified miR-146a, miR-21,
miR-142, and miR-15b as potential biomarkers, as well as con-
tributors to disease pathogenesis (Tang et al., 2020). Although
these studies are limited to a specific tissue, our data that
correlate miRNA signatures from multiple tissues (Figure 3)
suggest miR-2392 is a unique target that is ubiquitouslyinvolved in COVID-19 symptoms. To start addressing the
multi-tissue impact of miR-2392, we also show miR-2392 is
overexpressed in healthy monocyte cells infected with both
reference and P1 SARS-CoV-2 variants (Figure 5D). This may
indicate isolated cells will overexpress miR-2392 when in-
fected with SARS-CoV-2, and further work is being done to
investigate multi-tissue behavior of miR-2392.
Most miR-2392 publications are focused on cancer tissues,
where it may drive cellular invasion and metastasis. miR-
2392 was one of 6 miRNAs altered in the serum and tissue of
cervical cancer patients used to predict metastasis (Chen
et al., 2013). Higher levels of miR-2392 in gastric cancer were
linked to lower clinical staging and increased patient survival (Li
et al., 2017) by inhibiting invasion and metastasis via the loss of
Snail1, Slug, and Twist1 expression. Similarly, lower miR-2392
and miR-1587 levels were found in human keloid tissues that
led to a loss of inhibition of ZEB2 and promoted cellular
proliferation and invasion (Hou et al., 2017). Recently, a role
for miR-2392 in tongue squamous cell carcinoma showed par-
tial inhibition of transcription through direct miRNA-mtDNACell Reports 37, 109839, October 19, 2021 11
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OPEN ACCESSbase-pairing, resulting in reprogramming of tumor cell meta-
bolism and chemoresistance (Fan et al., 2019). These miR-
2392 reports establish the significant impact that this miRNA
may have on cellular activity. Particularly relevant here is the
more than 2-fold increase of miR-2392 in extracellular vesicles
of hepatitis B-infected human hepatocytes (Enomoto et al.,
2017). Although miR-2392 has a reported impact on tumor
cell biology, our study expands the valuable therapeutic poten-
tial of targeting miR-2392 to decrease SARS-CoV-2 viral infec-
tions (Figure 6). These results warrant further exploration of the
mechanistic underpinnings for the role of miR-2392 in driving
viral infection.
One therapeutic insight deduced from miR-2392 interac-
tions is the importance of the mitochondrial OXPHOS and
glycolytic pathways in COVID-19, which are dramatically high-
lighted in BALF samples (Figure 1C). In a study of tongue
squamous cell carcinoma (Fan et al., 2019), miR-2392 enters
the mitochondrion, where it binds Ago2 and nucleotides
4,379 to 4,401 in the mtDNA heavy (H) strand within the MT-
TQ (tRNA glutamine) gene (m.4329-4400). MT-TQ is part of a
large polycistronic transcript encompassing 12 of the mtDNA
H strand polypeptide genes punctuated by tRNAs. Cleavage
of the tRNAs releases the mRNAs. Upstream of MT-TQ are
the 12S and 16S rRNAs and the complex I gene MT-ND1
gene. Downstream of MT-TQ are MT-ND2, MT-CO1, MT-
CO2, MT-ATP6/8, MT-ND3, MT-ND4L, MT-ND4, MT-ND5,
and MT-CYB (Lott et al., 2013; Wallace, 2018). The downregu-
lated mtDNA genes are the complex IV (cytochrome c oxidase)
genes MT-CO1 and MT-CO2, the complex III (the bc1 com-
plex) gene (MT-CYB), and the complex I genes (MT-ND2,
MT-ND4, and MT-ND5) (Figure 1C, right side arc). Because
the miR-2392 inhibition of mtDNA OXPHOS genes (Figure 1C)
is also reflected in the downregulation of the nuclear DNA-
coded mitochondrial transcripts of the complex I and IV genes
and the iron-sulfur and heme iron complexes in the nasal,
heart, and kidney autopsy samples (Figure 3D), mitochondrial
inhibition by miR-2392 appears to be the only physiological
function that is common across all tissues in infected individ-
uals, suggesting mitochondrial modulation is a central feature
of SARS-CoV-2 pathophysiology.
The inhibition of mitochondrial genes by miR-2392 would
impair OXPHOS, which would have the most adverse effects
on the high mitochondrial energetic tissues (brain, heart, and
kidney), the tissues central to the most severe COVID-19
cases. Inhibition of mitochondrial OXPHOS genes would in-
crease mitochondrial reactive oxygen species (mROS) pro-
duction and induce glycolysis to compensate for the energy
deficit (see the top of Figure 1C). Mitochondrial function is
regulated by the sirtuins (Carrico et al., 2018), mitochondrial
decline is associated with senescence, and mROS oxidation
of mtDNA is linked to activation of the inflammasome and
thus NF-kB (West and Shadel, 2017; Zhong et al., 2018), all
of which are modulated around miR-2392 (Figure 1C). Thus,
SARS-CoV-2 induction of miR-2392 (Figure 5) and its associ-
ated inhibition of mtDNA and nuclear DNA OXPHOS genes
(Figures 3 and S1) could explain many metabolic disturbances
of COVID-19. Conversely, antagonism of miR-2392 function
should ameliorate the inhibition of OXPHOS and may explain12 Cell Reports 37, 109839, October 19, 2021the therapeutic benefit of the anti-miR-2392 nanoligomer
(Figure 6).
Exploiting miRNAs from serum as a biomarker was pioneered
in patients to examine diffuse large B cell lymphoma (Lawrie
et al., 2008). UsingmiRNAs as diagnostic biomarkers has several
advantages. Circulating miRNAs are readily obtained through a
minimally invasive blood draw and are remarkably resistant to
degradation in the plasma and serum (Mitchell et al., 2008).
They may provide a means to detect asymptomatic individuals
(Hou et al., 2017). However, potential confounding diseases
that may influence the expression of multiple miRNAs, which re-
quires further evaluation of the targets found in this study
(Figure 5).
Advances in RNA chemistry and delivery systems enabled
the first miRNA-based agents to enter into clinical trials several
years ago (Rupaimoole and Slack, 2017). miR-122 was found to
increase the stability and replication of the hepatitis C virus
(HCV) via binding that prevented degradation by the Xrn1 exo-
ribonuclease (Thibault et al., 2015). Following a phase I trial that
inhibited miR-122 with no adverse reactions, a phase IIa trial
showed a dose-dependent decrease in HCV load and one re-
ported grade 3 thrombocytopenia; in addition, only a small set
of patients experienced viral rebound that might be linked to
mutations of the HCV viral RNA (Janssen et al., 2013; Ottosen
et al., 2015). A separate trial targeting miR-122 reduced viral
loads in all treated patients within 4 weeks, with a sustained
response in 3 patients after 76 weeks (van der Ree et al.,
2017); however, trials were suspended due to two cases of se-
vere jaundice. These clinical trials have demonstrated the prom-
ising potential of using anti-miRNAs to significantly reduce viral
infection with limited adverse effects, and the similarities with
miR-2392 with SARS-CoV-2 warrant further investigations to
push to clinical trials.
Presently, there remains no specific treatment option for pa-
tients presenting with severe COVID-19. Although vaccines pro-
vide a promising avenue toward curbing the infection rate and
minimizing symptoms, there remains an urgency to successfully
develop and implement therapeutic agents to reduce severe
consequences and subsequent patient mortality from COVID-
19. Testing of antibody-based or drug-targeted therapies is un-
der way, andmiRNAs represent a category of therapeutic agents
that have previously shown endogenous activity to alter viral
infection.
Limitations of the study
We determined that miR-2392 is a key driver for SARS-CoV-2
infections and could be used as a biomarker of COVID-19 pos-
itivity. The specificity of the miRNAs, specifically miR-2392,
needs to be expanded by observing expression in multiple tis-
sues from COVID-19-infected patients and animal models.
From RNA-seq autopsy data, we determined genes altered
by miR-2392 in multiple organs, but further investigation is
warranted to quantify the presence of miRNAs in tissues.
Although the antiviral studies for miR-2392 are promising,
more studies are needed to improve efficacy and determine
whether this antiviral will provide an effective therapeutic op-
tion for COVID-19 patients. Lastly, the predicted top-ranked
drugs to target miR-2392 (Figure 7) need to be validated in a
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Afshin
Beheshti (afshin.beheshti@nasa.gov).
Materials availability
This study did not generate new unique reagents.
Data and code availability
The published article includes all datasets generated and analyzed during this study. Processed bulk RNA-seq data for the human
related data from the nasopharyngeal and autopsy data is available online with dbGaP Study Accession number: phs002258.v1.p1
and online here at: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002258.v1.p1 and also https://
covidgenes.weill.cornell.edu/. The RNA-sequence data related for the miR-2392 mimic experiments is deposited on SRA (https://
www.ncbi.nlm.nih.gov/sra) with BioProject ID: PRJNA76339.
This paper does not report original code.
Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human serum and nasopharyngeal swab sample collection for ddPCR
All plasma and nasal swab samples from those with COVID-19 infection, seasonal coronavirus infection, and controls were collected
from inpatients at the University of MarylandMedical Center, in Baltimore, USA, between March andMay of 2020. Sample collection
obtained through informed consent waiver, which was approved by the University of Maryland, Baltimore IRB.e3 Cell Reports 37, 109839, October 19, 2021
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were obtained. An equal distribution of N = 5males and females were used for each group. Also, an equal age distribution of patients
from 27 to 85 years old was utilized for each group.
For the nasopharyngeal samples the following patient samples were obtained: N = 10 SARS-CoV-2 positive patients, N = 6 com-
mon cold coronavirus samples, and N = 6 Coronavirus NL63 samples. For the common cold coronavirus samples the breakdown
was the following for the specific viruses: N = 2 Coronavirus 229E, Coronavirus HKU1, and N = 2 Coronavirus OC43.
Human nasopharyngeal swab sample collection for RNA-seq analysis
Patient specimens were processed as described in Butler et al. (2021). Briefly, nasopharyngeal swabs were collected using the BD
Universal Viral Transport Media system (Becton, Dickinson and Company, Franklin Lakes, NJ) from symptomatic patients. Total Nu-
cleic Acid (TNA) was extracted from using automated nucleic acid extraction on the QIAsymphony and the DSP Virus/Pathogen Mini
Kit (QIAGEN).
Human autopsy tissue collection for RNA-seq analysis
The full methods of the patient sample collection from the autopsy patients are currently available in the Park et al. (2021). All au-
topsies are performed with consent of next of kin and permission for retention and research use of tissue. Autopsies were performed
in a negative pressure room with protective equipment including N-95 masks; brain and bone were not obtained for safety reasons.
All fresh tissues were procured prior to fixation and directly into Trizol for downstream RNA extraction. Tissues were collected from
lung, liver, lymph nodes, kidney, and the heart as consent permitted. For GeoMx, RNAscope, trichrome and histology tissue
sections were fixed in 10% neutral buffered formalin for 48 hours before processing and sectioning. These cases had a post-mortem
interval of less than 48 hours. For bulk RNA-seq tissues, post-mortem intervals ranged from less than 24 hours to 72 hours (with 2
exceptions - one at 4 and one at 7 days - but passing RNA quality metrics) with an average of 2.5 days. All deceased patient remains
were refrigerated at 4C prior to autopsy performance.
Human urine sample collection
Urine was collected from patients and volunteers at the University of North Carolina at Chapel Hill. All patients provided informed
consent prior to participation in IRB-approved research protocols (UNC IRB: 20-0822 [RHS] and 20-0792 [NMB]). Mid-stream urine
of outpatients and non-critically ill patients was collected by the clean catch method. Urine of intubated critically ill patients was
collected from a port on the Foley catheter. Urine was aliquoted into 5 mL aliquots and stored at 80C. The following patient urine
samples were obtained: N = 10 inpatient patients positive for COVID-19, N = 10 inpatient COVID-19 negative patients, N = 15 outpa-
tient patients positive for COVID-19, N = 11 outpatient patients negative for COVID-19 (or healthy donors).
Urine aliquots were thawed, and microRNA was extracted from 1 mL per sample using Norgen Urine microRNA Purification Kit
(Cat. 29000). Microalbumin and creatinine levels were assessed using Microalbumin 2-1 Combo strips (CLIAwaived Inc, cat#
URS-2M).
Human peripheral blood mononuclear cells collection for ddPCR
Peripheral blood mononuclear cells (PBMC) were obtained from buffy coats (Hematology and Hemotherapy Center of the University
of Campinas) from healthy donors provided Study was approved by the Brazilian Committee for Ethics in Human Studies (CAEE:
31622420.0.0000.5404). PBMCs were isolated as described in Codo et al. (2020).
Cell lines used for miR-2392 mimic experiments
Human SH-SY5Y cells were obtained from the ATCC and grown in Minimum Essential Medium (GIBCO) / 10% FBS (Invitrogen) /1%
MEMNon Essential Amino Acids (GIBCO) / 1%GlutaMAX -l (GIBCO). Cells were plated in 3.5 cmdishes and incubatedwithmiR-2392
or control lentivirus particles (MOI 1) for 48h. Cells were harvested and lysed in Trizol reagent and RNA was extracted following man-
ufacturers protocol (Invitrogen).
COVID-19 hamster model
Male Syrian hamsters 6-8 weeks old were utilized for efficacy studies with anti-miR-2392 Nanoligomers treatment. Three hamsters
were used for each experimental group for a total of 30 hamsters with 10 treatment groups. Hamsters were infected with 105 pfu of
the WA01/2020 strain of SARS-CoV-2 passaged twice in Vero E6 cells from the original isolate obtained from BEI Resources. There
were 5 major treatment groups (N = 6 per group) with two endpoints at day 3 or 7 post-viral challenge (N = 3 per endpoint). Groups 1
and 3 were given the Nanoligomer treatment by Intraperitoneal (IP) injection while groups 2 and 4 were given by Intranasal (IN) instil-
lation under ketamine-xylazine anesthesia. Groups 1 and 2 were given single Nanoligomer treatment 24 hours before viral challenge.
Groups 3 and 4 were given two doses of Nanoligomer at 24 hours before and 24 hours after viral challenge. The control group 5 was
treated with PBS 24 hours prior to and 24 hours following viral challenge by IN instillation. A primary focus for the animal tests was to
assess treatment efficacy to reduce viral infection in the pulmonary system. Thus, the Nanoligomers were administered directly to
lung tissues via the IN route and the primary endpoints were specifically evaluated for oropharyngeal shedding of virus and lung tis-
sue burden for the virus at necropsy. Injecting the Nanoligomer intravenously (IV) may have also provided a suitable route to target theCell Reports 37, 109839, October 19, 2021 e4
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directly to the lungs.
Treatment efficacy was assessed in multiple ways: 1) Change in daily body weight, 2) oropharyngeal shedding of virus on days 1-3
from all groups post-challenge assayed by plaque assay on Vero E6 cells (PFU/swab), 3) tissue burden of the virus at necropsy on day
3 from 2 lung tubes and turbinates assayed by plaque assay (PFU/100mg), and 4) histopathologic scoring on lungs and turbinates
from all hamsters; the histopathological score for individual tissues, inflammation score from the interstitial lung inflammation, and
total histopathological scores/assessment was made.
The dose of anti-miR-2392 that was used was calculated to raise blood levels to 10 mM if it were given intravenously. The dose was
estimated from the average IC50s determined from our in vitro viral screening experiments. The molecular weight of anti-miR-2392 is
15,804. Assuming that hamsters weigh 120 g and have 8% of body weight as blood, blood volume was approximately 0.01 l. The
dose per hamster was 1.58 mg in a 100 mL volume from an anti-miR-2392 solution.
In vitro viral screening model
A549-ACE2 cells, gifted by Dr. Brad Rosenberg (MSSM), weremaintained in DMEM (Quality Biological, Gaithersburg, MD; #112-014-
101) + 10% Fetal Bovine Serum (GIBCO; #26140079) + 1% Penicillin-Streptomycin (Gemini Bio; #400-109). The day prior to treat-
ment, 5,000 A549-ACE2 cells were plated per well in 96-well plates. MiR-2932 was diluted in duplicate in A549-ACE2 media to a
starting concentration of 20 mM (Run 1) or 22 mM (Runs 2 and 3), and then an 8-point 1:2 dilution series was prepared. Media was
removed from cells and 90 mL of each dilution was transferred to the cells. The plates were incubated for 2 hours at 37C before being
infected with an M.O.I. of 0.1 SARS-CoV-2 WA-1 (provided by Dr. Natalie Thornburg at the Centers for Disease Control and Preven-
tion). Parallel plates were also run and left uninfected tomonitor toxicity. Since Runs 2 and 3were run simultaneously, a single toxicity
plate was run for both. All plates were incubated at 37C for 72 hours before being analyzed via Cell Titer Glo (Promega, Madison, WI;
#G7573). Cell viability was compared to uninfected, untreated cells and infected, untreated cells.
METHOD DETAILS
Human peripheral blood mononuclear cell infection with SARS-CoV-2
Monocytes were isolated from PBMCs as described in Toniolo et al. (2015). Cells were infected with SARS-CoV-2 B and P1 lineages
as described. B lineage virus was isolated from the second confirmed case in Brazil (GenBank: MT126808.1). P1 was obtained as
described by Souza et al. (2021).
miRNA extraction for Droplet Digital PCR (ddPCR)
MiRNA extractions from serum were carried out using the QIAGEN miRNeasy serum/plasma kit (#217184). MiRNA extractions from
urine samples were carried out using Norgen urine microRNA Purification Kit (Cat. 29000, Norgen Bioteck Corp. Thorold, ON, Can-
ada). Quantitation of miRNA samples was done using a NanoDrop 2000 Spectrophotometer (ThermoFisher Scientific).
cDNA generation and ddPCR
First, cDNA was synthesized from miRNA samples using the QIAGEN miRCURY LNA RT Kit (Cat. 339340) using a concentration of
5ng/ml for the miRNA per sample. Next, samples were mixed with a 1:20 dilution of the generated cDNA with the BioRad QX200
ddPCR Evagreen Supermix (Cat. 1864034) and the appropriate miRNA primers from miRCURY LNA miRNA PCR Assays (QIAGEN).
BioRad QX200 Automated Droplet Generator (Cat. 1864101) was used to create emulsion droplets. With the C1000 Touch Thermal
Cycler with 96–DeepWell Reaction Module (Bio-Rad) the following PCR reaction was used for all the primers: 1 cycle 95C for 5 min,
40 cycles of 95C for 30 s and 58C for 1 min (the annealing temperature can change depending on the primer), 1 cycle of 4C for
5 min, and 1 cycle of 90C for 5 min. Not all miRNA primers sets for ddPCR will have the same annealing temperature, so optimizing
the annealing temperature is required for each primer set. Their respective annealing temperatures are found in Table S1. Finally, the
QX200 Droplet Digital PCR System (Bio-Rad) quantified the amount of miRNA for each primer set per sample. QuantaSoft software
(Bio-Rad) generated the data for each primer set and sample. The same threshold settingwas used for all samples per primer set. The
concentration (miRNA copies/ml) value generated by QuantaSoft was converted to miRNA copies/ng of serum. These values were
used for all miRNA analysis. For all analysis the miRNA concentrations were log2(x+1) transformed to allow for easy comparison be-
tween miRNAs and samples.
Publicly available Bronchial Alveolar Lavage Fluid (BALF) COVID-19 RNA-sequencing data
Fastq files were downloaded from SRA (NCBI BioProject PRJNA605907 (Shen et al., 2020) and NCBI BioProject: PRJNA390194
(Ren et al., 2018)). Fastq data files were trimmed using TrimGalore v (0.6.4) with a quality cutoff of 30. Data were then aligned
using STAR (v2.7.3) two pass mode to the Human reference genome (GRCh38 v99 downloaded 04-27-2020). Unaligned data
were written to a fastq file, and then realigned to the GRCh38 reference genome using Bowtie 2 (v2.3.4.1), and output sam
file converted to a bam file using samtools (v1.7). The resultant Bam files were merged, sorted, and read groups added using
picard tools (v2.21.3).e5 Cell Reports 37, 109839, October 19, 2021
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RawRNA-seq read counts from the publication by Blanco-Melo et al. (2020) for the A549, Calu-3, andNHBE cell lines as well as post-
mortem lung biopsies from two COVID-19 patients were downloaded from the Gene Expression Omnibus (series accession
GSE147507).
RNA-seq of Nasopharyngeal Swab COVID-19 patient samples
RNA isolation and library preparation is fully described in Butler et al. (2021). Briefly, library preparation on the all nasopharyngeal
swab samples’ total nucleic acid (TNA) were treated with DNase 1 (ZymoResearch, Catalog # E1010). Post-DNase digested samples
were then put into the NEBNext rRNA depletion v2 (Human/Mouse/Rat), Ultra II Directional RNA (10 ng), and Unique Dual Index
Primer Pairs were used following the vendor protocols from New England Biolabs. Kits were supplied from a single manufacturer
lot. Completed libraries were quantified by Qubit or equivalent and run on a Bioanalyzer or equivalent for size determination. Libraries
were pooled and sent to the WCM Genomics Core or HudsonAlpha for final quantification by Qubit fluorometer (ThermoFisher Sci-
entific), TapeStation 2200 (Agilent), and qRT-PCR using the Kapa Biosystems Illumina library quantification kit.
RNA-seq of COVID-19 autopsy tissue samples
RNA isolation and library preparation is fully described in Park et al. (2021). Briefly, autopsy tissues were collected from lung, liver,
lymph nodes, kidney, and the heart and were placed directly into Trizol, homogenized and then snap frozen in liquid nitrogen. At
least after 24 hours these tissue samples were then processed via standard protocols to isolate RNA. New York Genome Center
RNA sequencing libraries were prepared using the KAPA Hyper Library Preparation Kit + RiboErase, HMR (Roche) in accordance
with manufacturer’s recommendations. Briefly, 50-200ng of Total RNA were used for ribosomal depletion and fragmentation.
Depleted RNA underwent first and second strand cDNA synthesis followed by adenylation, and ligation of unique dual indexed
adapters. Libraries were amplified using 12 cycles of PCR and cleaned-up by magnetic bead purification. Final libraries were
quantified using fluorescent-based assays including PicoGreen (Life Technologies) or Qubit Fluorometer (Invitrogen) and Fragment
Analyzer (Advanced Analytics) and sequenced on a NovaSeq 6000 sequencer (v1 chemistry) with 2x150bp targeting 60M reads
per sample.
miR-2392 mimic experiments in SH-SY5Y cells and RNA-seq
RNAwas dissolved in nuclease freewater and concentration determined spectrometrically at 260nmusing a Biotek plate reader (Bio-
tek). 500ng RNAwas used as input for a whole transcriptome library preparation (ThermoFisher Total RNA). Libraries were quantified
using a bioanalyzer chip reader (nanoDNA chips: Aglient Technologies) and diluted to 100 pM final concentration. Barcoded libraries
were combined and use to seed a OneTouch bead templating reaction (OneTouch2). Cloned libraries were enriched and loaded on
540 Ion Torrent chips. Data were sequenced using the Ion Torrent RNA-seq workflow. Unaligned Bam files were converted to fatsq
and aligned to the Grch 38 reference genome using STAR Two pass approach (Dobin et al., 2013) to create gene count tables as
described in Overbey et al. (2021). The raw RNA-sequence data was deposited on SRA (https://www.ncbi.nlm.nih.gov/sra) with Bio-
Project ID: PRJNA76339.
Anti-miR-2392 Nanoligomer inhibitor design and construction
The Nanoligomer platform was used to design Nanoligomer inhibitors, which are composed of a nanobiohydrd molecule based on
antisense peptide nucleic acid (PNA) moiety conjugated to nanoparticle for improved delivery and membrane transport. The PNA
moiety was chosen to be 15 bases long (in order to maximize both solubility and specificity), which yielded six potential target se-
quences within the 20-nucleotide mature human miR-2392. These potential targets were screened using FAST for solubility, self-
complementing sequences, and off-targeting within the human genome (GCF_000001405.26) and SARS-CoV-2 viral genome
(NC_045512). The antisense sequence complementing miR-2392 nucleotides 2 to 16 (TCTCACCCCCATCCT) was chosen in order
to minimize off-targeting while maximizing coverage of the miR-2392 seed region. The Nanoligomer was synthesized (with an N-ter-
minal histidine tag and a 2-(2-(2-aminoethoxy)ethoxy)acetic acid linker) on an Apex 396 peptide synthesizer (AAPPTec, LLC) with
solid-phase Fmoc chemistry. Fmoc-PNA monomers were obtained from PolyOrg Inc., with A, C, and G monomers protected with
Bhoc groups. Following synthesis, the peptides were conjugated with nanoparticles and purified via size-exclusion filtration. Conju-
gation and concentration of the purified solution was monitored through measurement of absorbance at 260 nm (for detection of
PNA) and 400 nm (for quantification of nanoparticles).
QUANTIFICATION AND STATISTICAL ANALYSIS
Analysis of BALF RNA-seq data
Bam files were imported into Partek Genome Studio v7.0, and gene expression values quantified versus the Grch38 reference anno-
tation guide (Ensembl v99). Samples with fewer than 2 million aligned reads were excluded from further analysis. Genes with fewer
than 10 reads in 25% of samples were excluded, and differential gene expression determined using ANOVA with infection status as
contrast. Differentially expressed gene files were used in GSEA and IPA to determine biological significance and pathways being
regulated.Cell Reports 37, 109839, October 19, 2021 e6
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The nasopharyngeal swab samples were analyzed comparing COVID-19 viral infection to the negative patients and was as pre-
viously described in Butler et al. (2021) and the DESeq2 (Love et al., 2014) was utilized to generate the differential expression data.
Heatmaps were displayed using pheatmap (Kolde, 2015). Volcano plots were made use R program EnhancedVolcano (Blighe
et al., 2018).
Analysis of Autopsy RNA-seq data
The full methods of the analysis from the autopsy patients is currently available in Park et al. (2021). Briefly, RNA-seq data was pro-
cessed through the nf-core/rnaseq pipeline (Ewels et al., 2020). This workflow involved adaptor trimming using Trim Galore! (https://
github.com/FelixKrueger/TrimGalore), read alignment with STAR (Dobin et al., 2013), gene quantification with Salmon (Patro et al.,
2017), duplicate read marking with Picard MarkDuplicates (https://github.com/broadinstitute/picard), and transcript quantification
with StringTie (Kovaka et al., 2019). Other quality control measures included RSeQC, Qualimap, and dupRadar. Alignment was per-
formed using the GRCh38 build native to nf-core and annotation was performed using Gencode Human Release 33 (GRCH38.p13).
FeatureCounts reads were normalized using variance-stabilizing transform (vst) in DESeq2 package in R for visualization purposes in
log-scale (Love et al., 2014). Differential expression of genes were calculated by DESeq2. Differential expression comparisons were
done as either COVID+ cases versus COVID- controls for each tissue specifically, correcting for sequencing batches with a covariate
where applicable, or pairwise comparison of viral levels from the lung as determined by nCounter data. Volcano plots were made use
R program EnhancedVolcano (Blighe et al., 2018).
Analysis Combining Autopsy and Nasopharyngeal Swab RNA-seq data
To combine the results from the autopsy and nasopharyngeal swab RNA-seq data, we utilized the t-score values from the DESeq2
analysis. Heatmaps were displayed using pheatmap (Kolde, 2015).
Gene Set Enrichment Analysis (GSEA)
For pathway analysis on the miR-2392 targets (Figure 3) we utilized ShinyGO (Ge et al., 2020) to determine the significantly regulated
pathways for each main cluster in the heatmap. The clustering was determined through k-mean statistics.
For pathway analysis on the miR-2392 mimic RNA-seq data, we utilized fast Gene Set Enrichment Analysis (fGSEA) (Korotkevich
et al., 2021). Pathway analysis was done comparing miR-2392 mimics to all controls and the ranked list of genes were defined by the
t-score statistics. The statistical significance was determined by 1000 permutations of the genesets (Subramanian et al., 2005).
Analysis of proteomic and transcriptomic blood datasets from COVID-19 patients
For the analysis of the miR-2392 targets in the blood tissue, we downloaded whole blood transcriptome data and plasma proteome
data from The COVIDome Explorer Researcher Portal (Sullivan et al., 2021). For Transcriptome data we used the following filters:
Category ‘‘Effect of COVID-19 status,’’ Platform ‘‘Blood,’’ Statistical test ‘‘Student’s t-test,’’ Adjustment method ‘‘none,’’ Sex
‘‘male’’ and ‘‘female,’’ Age Group ‘‘All.’’ For Proteome data we used the following filters: Category ‘‘Effect of COVID-19 status,’’ Plat-
form ‘‘SOMAscan,’’ Statistical test ‘‘Student’s t-test,’’ Adjustment method ‘‘none,’’ Sex ‘‘male’’ and ‘‘female,’’ Age Group ‘‘All.’’ We
created the list of the intersecting genes from both datasets. We analyzed the list using RStudio Desktop 1.3.1093 (R Studio Team,
2020). RStudio: Integrated Development Environment for R. RStudio, PBC, Boston, MA URL https://www.rstudio.com/), and visual-
ized data using ggplot2 version 3.3.2 (Wickham, 2016) and ggrepel version 0.8.2 (https://ggrepel.slowkow.com/).
Analysis of Monocyte RNA-seq data
The monocyte COVID-19 RNA-Seq data, published under the accession GSE159678 (Rother et al., 2020), was downloaded from
SRA and gene expression was quantified using Salmon’s selective alignment approach (Srivastava et al., 2020). The RNA-Seq pro-
cessing pipeline was implemented using pyrpipe (Singh et al., 2021) (https://github.com/urmi-21/pyrpipe/tree/master/case_studies/
Covid_RNA-Seq). Exploratory data analysis and differential expression analysis were performed using MetaOmGraph (Singh et al.,
2020).
Analysis of A549, Calu-3, NHBE, and COVID lung biopsy data
Each data series was normalized and filtered for low-expressed genes (counts < 1). Cell culture samples treated with SARS-CoV-2
were compared to untreated controls and COVID-19-positive patient samples were compared to healthy lung biopsies. Differentially
expressed genes were determined from the R-program Limma-Voom (Ritchie et al., 2015) using a linear model with weighted least-
squares for each gene and the false discovery rate adjusted p values were calculated.
Analysis of miR-2392 mimic RNA-seq data
Differential gene expression was determined using LIMMA-voom (Ritchie et al., 2015). Data were filtered to ensure data contained at
least 5 million aligned reads, and average gene counts of > 10. Cell treatments we used as contrasts for differentially expressed gene
calculations. These results were then uploaded to GSEA for further analysis. (R script in Supplemental information)e7 Cell Reports 37, 109839, October 19, 2021
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OPEN ACCESSConservation of miR-2392 between species
To determined conservation of miR-2392 among different species we utilized UCSC Genome Browser (Kent et al., 2002). Hsa-miR-
2392 was entered as input and target species were chosen to include common models for SARS-CoV-2 in vivo studies (e.g., mice,
ferrets, and hamsters) as well as primates and other animals to provide a wide spectrum of species to observe conservation of miR-
2392. The USCSGenome Browser provides the host gene for miR-2392 (i.e., MEG3) and redirects to GTEx (GTEx Consortium, 2020)
to provide a plot of MEG3 levels based on RNA-seq data on normal tissues.
Mapping miR-2392 sequence to SARS-CoV-2 sequences
To explore potential binding sites for miR-2392 we used miRanda software (Enright et al., 2003) to identify all potential binding sites
with respect to the SARS-CoV-2 reference genome (Wuhan-Hu-1; NC045512.2) and representative genomes from lineages of
concern. The lineages of concern were selected from Global Initiative on Sharing All Influenza Data (GISAID) with each lineage being
represented by 14 recent genomes.
In silico predictions of genes from miRNAs
Through the use of a Cytoscape (Shannon et al., 2003) plug-in called ClueGo/CluePedia (Bindea et al., 2009), we were able to predict
genes targeted by the miRNAs determined. This involved entering all miRNAs in ClueGo and allowing the software to determine the
top 50 genes that were significantly regulated and connected to the miRNAs. The predictions only reflect the functions that will be
regulated by the miRNAs and do not show whether the function will be activated or inhibited. Lastly, miRNet 2.0 was utilized to
predict the diseases and pathways that are associated with the miRNAs (Chang et al., 2020). This was plotted as a dot plot utilizing
the R-program ggplot2 (v3.2.1) (Wickham, 2016).
ddPCR analysis of miRNA levels in patient samples
First, we normalized the amount of each miRNA measured per body location (nasal, serum, and urine) using the general logarithm
transformation. We compared miRNA levels in samples from patients either positive or negative for SARS-nCoV-2 using the Stu-
dent’s t test (unadjusted) as well as controlling for sex and age using least-squares adjustment. Next, we generated receiver oper-
ating characteristic curves from each body location to show the performance of a classificationmodel (SARS-nCoV-2 positive versus
negative) at all classification thresholds using the absolute, non-transformed levels (miRNA copies per 5 ng RNA). Finally, we per-
formed a subanalysis on each location to compare the variance of eachmiRNA in SARS-nCoV-2 negative patients compared to other
patient groups. For serum and nasal samples, 1-way ANOVA was used to identify variation associated with the patient classification.
For urine samples, 2-way ANOVA was used with location (outpatient versus inpatient) and SARS-nCoV-2 positivity as the main fac-
tors. If the ANOVA yielded a p < 0.05, Dunnett’s post-test was used to compare subgroup means to the negative patient sample
mean.
Computational drug repositioning model
Using the SM2miR database (Lui et al., 2007), we assembled an n3m binary matrix (X) containing 3,593 associations between small
molecules (n = 213, rows) andmiRNAs (m= 1,519, columns). Eachmatrix entry (Xij) was assigned a value of 1 where a small molecule
is known to be associated to miRNA, and was 0 otherwise. The chemical notation as a simplified molecular input line entry system
(SMILES) was obtained for each small molecule from PubChem. We then calculated the 2D Tanimoto chemical similarity between
pairs of small molecules using the MACCS key binary fingerprints with RDKit (RDKit: Open-source cheminformatics; http://www.
rdkit.org). Similarly, for each miRNA, we obtained its sequence from miRbase (Kozomara et al., 2019) and computed sequence sim-
ilarity between miRNAs as the score of their Needleman-Wunsch alignment. We used the binary matrix, together with the chemical
and sequence similarities, as input to our state-of-the-art drug target prediction model to predict missing associations in X (Galeano
et al., 2021). The model parameters where: p = 1/2, bChem = 1, and aseq = 0. To assess the prediction performance of the model, we
performed ten-fold cross-validation simulations.Cell Reports 37, 109839, October 19, 2021 e8
